CGS-20625

CGS-20625
	File:CGS-20625.svg
Clinical data
Routes of; administration	oral
Pharmacokinetic data
Bioavailability	41%
Identifiers
	IUPAC name 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one;
CAS Number	111205-55-1;
PubChem CID	163844;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H19N3O2
Molar mass	309.36236 g/mol
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2;

CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to, and binds to the same target as benzodiazepine drugs,^[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.^[2]^[3]

CGS-20625 produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects.^[4] It is orally active in humans, but with relatively low bioavailability.^[5]

Template:Pharmacology-stub

References

↑ Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits. Molecular Pharmacology. 2006 Feb;69(2):640-9. PMID 16272224
↑ Bennett DA. Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions. Physiology & Behaviour. 1987;41(3):241-5.PMID 2893398
↑ Brunner LA, Luders RC. Determination of a potential anxiolytic drug (CGS 20625) in human plasma by high-performance liquid chromatography. Journal of Chromatography. 1991 Aug 23;568(2):487-93. PMID 1686029
↑ Williams M, Bennett DA, Loo PS, Braunwalder AF, Amrick CL, Wilson DE, Thompson TN, Schmutz M, Yokoyoma N, Wasley JW. CGS 20625, a novel pyrazolopyridine anxiolytic. Journal of Pharmacology and Experimental Therapeutics. 1989 Jan;248(1):89-96. PMID 2563294
↑ Hirschberg Y, Oberle RL, Ortiz M, Lau H, Markowska M. Oral absorption of CGS-20625, an insoluble drug, in dogs and man. Journal of Pharmacokinetics and Biopharmaceutics. 1995 Feb;23(1):11-23. PMID 8576841

Template:Anxiolytics Template:WikiDoc Sources

[1] Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits. Molecular Pharmacology. 2006 Feb;69(2):640-9. PMID 16272224

[2] Bennett DA. Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions. Physiology & Behaviour. 1987;41(3):241-5.PMID 2893398

[3] Brunner LA, Luders RC. Determination of a potential anxiolytic drug (CGS 20625) in human plasma by high-performance liquid chromatography. Journal of Chromatography. 1991 Aug 23;568(2):487-93. PMID 1686029

[4] Williams M, Bennett DA, Loo PS, Braunwalder AF, Amrick CL, Wilson DE, Thompson TN, Schmutz M, Yokoyoma N, Wasley JW. CGS 20625, a novel pyrazolopyridine anxiolytic. Journal of Pharmacology and Experimental Therapeutics. 1989 Jan;248(1):89-96. PMID 2563294

[5] Hirschberg Y, Oberle RL, Ortiz M, Lau H, Markowska M. Oral absorption of CGS-20625, an insoluble drug, in dogs and man. Journal of Pharmacokinetics and Biopharmaceutics. 1995 Feb;23(1):11-23. PMID 8576841

[1]

[2]

[3]

[4]

[5]

Clinical data
File:CGS-20625.svg
Routes of administration	oral
Pharmacokinetic data
Bioavailability	41%
Identifiers
IUPAC name 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
CAS Number	111205-55-1
PubChem CID	163844
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₈H₁₉N₃O₂
Molar mass	309.36236 g/mol
3D model (JSmol)	Interactive image
SMILES COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2

CGS-20625

References

Navigation menu